Ir para o conteúdo principal

Sunshine Biopharma (NASDAQ: SBFM) — Perfil da empresa, notícias e dados financeiros

Logo de Sunshine Biopharma
SBFM Sunshine Biopharma
Sunshine Biopharma primary media
Perfil da empresa

Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM) is a dynamic entity engaged in the development of innovative pharmaceuticals aimed at treating cancer and other acute medical conditions. This company is distinguished by its commitment to advancing research and development in the pharmaceutical field, focusing on creating drugs that target the unmet needs of patients battling serious diseases. Sunshine Biopharma's efforts are driven by a goal to bring groundbreaking treatments from the lab bench to the bedside, demonstrating an unwavering dedication to improving patient outcomes. The company's operations span across the intricate landscape of pharmaceutical research, showcasing a robust pipeline of projects that promise to redefine therapeutic approaches in oncology and beyond. Through its relentless pursuit of excellence in healthcare innovation, Sunshine Biopharma strives to achieve its objectives of providing new, effective options for treatment and advancing the global pharmaceutical industry.

Resumo

Public USParticipação acionária
2006Ano de fundação
44Funcionários
Fort Lauderdale, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Fort Lauderdale, US

Produtos e/ou serviços de Sunshine Biopharma

  • Adva-27a, a unique anticancer compound targeting multidrug-resistant cancers.
  • Generic version of the anticancer drug Plitidepsin to treat COVID-19 in collaboration with the University of Georgia.
  • Development of novel small molecules for targeted therapy of various cancers.
  • Research into Coronavirus treatments including COVID-19, focusing on new therapeutic approaches.
  • Manufacturing and distribution of essential generic pharmaceuticals for various conditions.
  • Exploration of potential treatments for other viral diseases beyond COVID-19, leveraging their expertise in virology.

equipe executiva do Sunshine Biopharma

  • Steve N. SlilatyChairman, President & CEO
  • Camille SebaalyCFO, Secretary & Director
  • Michel RoyChief Commercial Officer
  • Malek ChamounChief Development Officer
  • Robert G. FerreiraPresident of Sunshine Bio Investments Inc

Comunicados recentes

O que a Sunshine Biopharma (SBFM) comunicou ao mercado, do mais recente para o mais antigo.

  1. LULD halt | SBFMFato relevante
  2. LULD halt | SBFMFato relevante
  3. LULD halt | SBFMFato relevante
  4. LULD halt | SBFMFato relevante
  5. LULD halt | SBFMFato relevante
  6. LULD halt | SBFMFato relevante
  7. LULD halt | SBFMFato relevante
  8. LULD halt | SBFMFato relevante

Principais indicadores financeiros

Resultados divulgados pela Sunshine Biopharma, em USD.

Cap. de mercado
2,4 mi
Receita (TTM)
35,3 mi
P/L
—
LPA (diluído, TTM)
-189.0
Dividend yield
—
Margem de lucro
-16.5%
Receita e lucro anuais da Sunshine Biopharma
Fim do ano fiscalReceitaResultado operacionalLucro líquido
36,3 mi-4,5 mi-6 mi
34,9 mi-5,8 mi-5,1 mi
24,1 mi-4,8 mi-4,5 mi
4,3 mi-8,7 mi-26,7 mi